Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: A phase 1 expansion cohort in patients with relapsed or refractory lymphoma

Kyriakos P. Papadopoulos, Coumaran Egile, Rodrigo Ruiz-Soto, Jason Jiang, Weiliang Shi, Frauke Bentzien, Drew Rasco, Pau Abrisqueta, Julie Marie Vose, Josep Tabernero

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The maximum tolerated dose of SAR245409 (voxtalisib), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, was determined in a phase 1 dose-escalation study in advanced solid tumors. We report safety, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of SAR245409 capsules 50 mg twice daily in an expansion cohort of 16 patients with relapsed/refractory lymphoma. The most common treatment-related adverse events (AEs) were nausea (31.3%) and diarrhea (25.0%). The most common grade 3/4 treatment-related AE was increased alanine aminotransferase (12.5%). PK results were consistent with solid tumors, confirming a relatively short steady-state half-life (mean 4.61 h). Among 12 evaluable patients, one complete response and two partial responses were achieved in patients with and without PI3K/mTOR pathway alterations. In a patient with mantle cell lymphoma achieving PR, SAR245409 was associated with significant inhibition of PI3K/mTOR and extracellular signal-related kinase (ERK) pathways. Preliminary efficacy warrants further evaluation of SAR245409 in lymphoma.

Original languageEnglish (US)
Pages (from-to)1763-1770
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

1-Phosphatidylinositol 4-Kinase
Sirolimus
Lymphoma
Pharmacokinetics
Safety
Mantle-Cell Lymphoma
Maximum Tolerated Dose
Alanine Transaminase
Nausea
Capsules
Half-Life
Diarrhea
Neoplasms
Phosphotransferases
XL765
Therapeutics

Keywords

  • Lymphoma
  • MTOR
  • PI3K
  • Pharmacodynamics
  • Pharmacokinetics
  • Signaling therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor : A phase 1 expansion cohort in patients with relapsed or refractory lymphoma. / Papadopoulos, Kyriakos P.; Egile, Coumaran; Ruiz-Soto, Rodrigo; Jiang, Jason; Shi, Weiliang; Bentzien, Frauke; Rasco, Drew; Abrisqueta, Pau; Vose, Julie Marie; Tabernero, Josep.

In: Leukemia and Lymphoma, Vol. 56, No. 6, 01.06.2015, p. 1763-1770.

Research output: Contribution to journalArticle

Papadopoulos, Kyriakos P. ; Egile, Coumaran ; Ruiz-Soto, Rodrigo ; Jiang, Jason ; Shi, Weiliang ; Bentzien, Frauke ; Rasco, Drew ; Abrisqueta, Pau ; Vose, Julie Marie ; Tabernero, Josep. / Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor : A phase 1 expansion cohort in patients with relapsed or refractory lymphoma. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 6. pp. 1763-1770.
@article{51c108a7b1184baebc4f905736a577df,
title = "Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: A phase 1 expansion cohort in patients with relapsed or refractory lymphoma",
abstract = "The maximum tolerated dose of SAR245409 (voxtalisib), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, was determined in a phase 1 dose-escalation study in advanced solid tumors. We report safety, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of SAR245409 capsules 50 mg twice daily in an expansion cohort of 16 patients with relapsed/refractory lymphoma. The most common treatment-related adverse events (AEs) were nausea (31.3{\%}) and diarrhea (25.0{\%}). The most common grade 3/4 treatment-related AE was increased alanine aminotransferase (12.5{\%}). PK results were consistent with solid tumors, confirming a relatively short steady-state half-life (mean 4.61 h). Among 12 evaluable patients, one complete response and two partial responses were achieved in patients with and without PI3K/mTOR pathway alterations. In a patient with mantle cell lymphoma achieving PR, SAR245409 was associated with significant inhibition of PI3K/mTOR and extracellular signal-related kinase (ERK) pathways. Preliminary efficacy warrants further evaluation of SAR245409 in lymphoma.",
keywords = "Lymphoma, MTOR, PI3K, Pharmacodynamics, Pharmacokinetics, Signaling therapies",
author = "Papadopoulos, {Kyriakos P.} and Coumaran Egile and Rodrigo Ruiz-Soto and Jason Jiang and Weiliang Shi and Frauke Bentzien and Drew Rasco and Pau Abrisqueta and Vose, {Julie Marie} and Josep Tabernero",
year = "2015",
month = "6",
day = "1",
doi = "10.3109/10428194.2014.974040",
language = "English (US)",
volume = "56",
pages = "1763--1770",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor

T2 - A phase 1 expansion cohort in patients with relapsed or refractory lymphoma

AU - Papadopoulos, Kyriakos P.

AU - Egile, Coumaran

AU - Ruiz-Soto, Rodrigo

AU - Jiang, Jason

AU - Shi, Weiliang

AU - Bentzien, Frauke

AU - Rasco, Drew

AU - Abrisqueta, Pau

AU - Vose, Julie Marie

AU - Tabernero, Josep

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The maximum tolerated dose of SAR245409 (voxtalisib), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, was determined in a phase 1 dose-escalation study in advanced solid tumors. We report safety, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of SAR245409 capsules 50 mg twice daily in an expansion cohort of 16 patients with relapsed/refractory lymphoma. The most common treatment-related adverse events (AEs) were nausea (31.3%) and diarrhea (25.0%). The most common grade 3/4 treatment-related AE was increased alanine aminotransferase (12.5%). PK results were consistent with solid tumors, confirming a relatively short steady-state half-life (mean 4.61 h). Among 12 evaluable patients, one complete response and two partial responses were achieved in patients with and without PI3K/mTOR pathway alterations. In a patient with mantle cell lymphoma achieving PR, SAR245409 was associated with significant inhibition of PI3K/mTOR and extracellular signal-related kinase (ERK) pathways. Preliminary efficacy warrants further evaluation of SAR245409 in lymphoma.

AB - The maximum tolerated dose of SAR245409 (voxtalisib), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, was determined in a phase 1 dose-escalation study in advanced solid tumors. We report safety, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of SAR245409 capsules 50 mg twice daily in an expansion cohort of 16 patients with relapsed/refractory lymphoma. The most common treatment-related adverse events (AEs) were nausea (31.3%) and diarrhea (25.0%). The most common grade 3/4 treatment-related AE was increased alanine aminotransferase (12.5%). PK results were consistent with solid tumors, confirming a relatively short steady-state half-life (mean 4.61 h). Among 12 evaluable patients, one complete response and two partial responses were achieved in patients with and without PI3K/mTOR pathway alterations. In a patient with mantle cell lymphoma achieving PR, SAR245409 was associated with significant inhibition of PI3K/mTOR and extracellular signal-related kinase (ERK) pathways. Preliminary efficacy warrants further evaluation of SAR245409 in lymphoma.

KW - Lymphoma

KW - MTOR

KW - PI3K

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Signaling therapies

UR - http://www.scopus.com/inward/record.url?scp=84932147143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932147143&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.974040

DO - 10.3109/10428194.2014.974040

M3 - Article

C2 - 25300944

AN - SCOPUS:84932147143

VL - 56

SP - 1763

EP - 1770

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -